Home Newsfeeds Citigroup Maintains Buy on SLB, Raises Price Target to $67

Citigroup Maintains Buy on SLB, Raises Price Target to $67

Citigroup analyst Scott Gruber maintains SLB (NYSE:SLB) with a Buy and raises the price target from $62 to $67.

byBenzinga Newsdesk

January 24, 2023

1 minute read

Citigroup analyst Scott Gruber maintains SLB (NYSE:SLB) with a Buy and raises the price target from $62 to $67.

Pfizer’s Diversity Program Faces Legal Heat, Advocacy Group Revives Discrimination Case

By Vandana Singh

October 4, 10:25 AM

Advocacy group Do No Harm has made a case before the New York-based 2nd U.S.

PFE

FDA
News

Veru Announces Oct. 6 Date For FDA Advisory Committee Meeting To Review Emergency Use Authorization For Sabizabulin For Hospitalized COVID-19 Patients At High Risk For Acute Respiratory Distress Syndrome

By Bill Haddad

September 7, 1:46 PM

MIAMI, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast

VERU

Analyst Ratings

Analyst Scoreboard: 4 Ratings For Cerence

By Benzinga Insights

April 17, 8:01 AM

4 analysts have shared their evaluations of Cerence (NASDAQ:CRNC) during the recent three months, expressing a mix of…

CRNC

News

Shareholder Approval Received For All Proposals At MICT Annual Shareholder Meeting

By Benzinga Newsdesk

December 30, 9:57 AM

MICT, Inc. (NASDAQ:MICT) ("MICT") announced today the results of the proxy vote associated with the Company's Annual Shareholders' Meeting. The shareholders approved all five of the resolutions

MICT

Citigroup Maintains Buy on SLB, Raises Price Target to $67

Related Posts

Pfizer’s Diversity Program Faces Legal Heat, Advocacy Group Revives Discrimination Case

Veru Announces Oct. 6 Date For FDA Advisory Committee Meeting To Review Emergency Use Authorization For Sabizabulin For Hospitalized COVID-19 Patients At High Risk For Acute Respiratory Distress Syndrome

Analyst Scoreboard: 4 Ratings For Cerence

Shareholder Approval Received For All Proposals At MICT Annual Shareholder Meeting